Medline Recalls Homecare Beds Over Fire Hazard Risk
Medline Industries recalled 373,392 homecare beds on November 26, 2025, due to a fire hazard. The hand control pendant can overheat, causing sparking or burning. The recall affects models MDR107002E and MDR107002E-4 sold in the U.S. and Canada.
Quick Facts at a Glance
Recall Date
November 26, 2025
Hazard Level
HIGH
Brand
Medline Industries, LP
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
3 states
At-Risk Groups
GENERAL
Hazard Information
Medline Industries has identified a potential hazard involving the hand control pendant and associated wires. In rare and atypical scenarios such as operating the bed above its specified weight limit, encountering an obstruction to bed movement, or experiencing jammed components/motor the hand pendant and pendant cords may overheat and, in rare instances, pose a risk of fire. Medline Industries, LP has received a total of (58) complaints associated with reports of pendant sparking, burning, melting, smoking or fire.
What You Should Do
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Medline Industries, LP or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
No spamUnsubscribe anytime
Product Details
The recalled products include the Semi Electric Basic Homecare Bed, REF MDR107002E, and the 4-pack version, REF MDR107002E-4. These beds were sold in the U.S., Canada, Puerto Rico, Guam, and the U.S. Virgin Islands.
The Hazard
The hand control pendant and associated wires may overheat under certain conditions, such as exceeding weight limits or encountering obstructions. This overheating can lead to sparking, burning, or, in rare cases, fire.
Reported Incidents
Medline received 58 complaints regarding issues with the hand pendant, including sparking, burning, melting, and smoke. No injuries or deaths have been reported.
What to Do
Patients and healthcare providers should stop using the affected beds immediately. They should contact Medline Industries or their healthcare provider for specific instructions regarding the recall.
Contact Information
For more information, contact Medline Industries at their website or customer service line. Visit the FDA recall page for further details.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.